1-2 of 2
Georges Rivard
Close
Sort by
Journal Articles

99.3% of Inhibitors in Severe Hemophilia a Develop before Exposure Day 75. Time to Change Definition of Previously Treated Patients; Data from 1038 Patients with Severe Hemophilia a of the Pednet Registry

Marijke Van den Berg, MD PhD, Kathelijn Fischer, Elena Santagostino, Herve Chambost, Karin Kurnik, Gili Kenet, MD, Christoph Male, MD, Anne Rafowicz, Helen Platokouki, Susanna Ranta, MD PhD, Christel Van Geet, MD, Johannes Oldenburg, Ri Liesner, Segolene Claeyssens, MD, Nadine Gretenkort-Andersson, Anne Mäkipernaa, PhD, Torben Stamm Mikkelsen, Manuel Carcao, Beatrice Nolan, Liz Chalmers, A.R. Cid, Teresa Álvarez-Roman, Carmen Altisent, Georges Rivard, MD FRCPC, Claudio Molinari, Martina Buehrlen, Rainer Kobelt, Carmen Escuriola, Manuela Carvalho, Christoph Koenigs, MD PhD, Mike Williams, Rolf Ljung, MD PhD Professor
Journal: Blood
Blood (2018) 132 (Supplement 1): 2472.
https://doi.org/10.1182/blood-2018-99-114518
Published: 2018
Journal Articles

The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study

Paula D. James, Colleen Notley, Carol Hegadorn, Jayne Leggo, Angie Tuttle, Shawn Tinlin, Christine Brown, Chandler Andrews, Andrea Labelle, Yvette Chirinian, Lee O'Brien, Maha Othman, Georges Rivard, Dilys Rapson, Christine Hough, David Lillicrap, for the Association of Hemophilia Clinic Directors of Canada
Journal: Blood
Blood (2006) 109 (1): 145–154.
https://doi.org/10.1182/blood-2006-05-021105
Published: 2006